Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06240351 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
A Phase 4 study of Frontal Fibrosing Alopecia, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06240351 is a Phase 4 study of Frontal Fibrosing Alopecia that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06240351, a Phase 4 study of Frontal Fibrosing Alopecia, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).
Conditions Studied
Interventions
- DRUG Baricitinib 4 MG Oral Tablet
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06240351
The ClinicalTrials.gov registry entry for NCT06240351 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Frontal Fibrosing Alopecia appearing as the primary indexed condition, and to 1 intervention - of which Baricitinib 4 MG Oral Tablet is the first listed.
NCT06240351 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT06240351 about?
NCT06240351 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)". The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).
What is the current status of trial NCT06240351?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2024-04-22. Estimated completion is 2027-07-31.
What conditions does trial NCT06240351 study?
This clinical trial studies the following conditions: Frontal Fibrosing Alopecia.
What interventions are being tested in trial NCT06240351?
The interventions under investigation include: Baricitinib 4 MG Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06240351?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06240351 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.